Sinobioway Medicine(SZ:002581) Zheng Quan Zhi Xing·2025-08-19 11:12Group 1 - The board meeting of Shandong Weiming Bio-Pharmaceutical Co., Ltd. was held on August 19, 2025, with all 11 directors participating [1] - The board approved the 2025 semi-annual report in full and summary, which was previously reviewed by the audit committee [2] - The board confirmed that there were no violations regarding the occupation of non-operating funds by controlling shareholders or related parties in the first half of 2025 [2][3] Group 2 - The board approved the cancellation of 16,617,396 stock options from the 2023 stock option incentive plan that were not exercised by 68 incentive objects by May 29, 2025 [2][3] - The cancellation of the stock options was within the authorization range granted by the company's first extraordinary general meeting in 2023 and did not require further shareholder approval [2][3]